Amylyx Pharmaceuticals In... (AMLX)
3.31
-0.18 (-5.16%)
At close: Jan 28, 2025, 1:58 PM
Income Statement (Annual)
Get detailed income statement breakdowns, uncovering revenue, expenses, and much more.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 |
| Revenue | 380.79M | 22.23M | 285.00K | 650.00K | 1.43M |
| Cost of Revenue | 25.44M | 2.99M | 52.00K | 24.59M | 11.90M |
| Gross Profit | 355.35M | 19.24M | 233.00K | -23.94M | -10.47M |
| Operating Income | 38.80M | -201.34M | -82.69M | -39.01M | -13.55M |
| Interest Income | 16.16M | 4.29M | 36.00K | 14.00K | 176.00K |
| Pretax Income | 54.30M | -197.60M | -87.93M | -42.28M | -13.72M |
| Net Income | 49.27M | -198.38M | -87.88M | -44.84M | -14.82M |
| Selling & General & Admin | 188.36M | 127.13M | 38.93M | 15.06M | 3.08M |
| Research & Development | 128.19M | 93.45M | 44.04M | 24.59M | 11.90M |
| Other Expenses | n/a | 3.74M | -285.00K | -650.00K | -1.43M |
| Operating Expenses | 316.54M | 220.58M | 82.69M | 39.01M | 13.55M |
| Interest Expense | n/a | 4.29M | n/a | 2.29M | 1.28M |
| Selling & Marketing Expenses | 9.50M | 4.40M | n/a | n/a | n/a |
| Cost & Expenses | 341.98M | 223.57M | 82.69M | 39.01M | 13.55M |
| Income Tax | 5.03M | 774.00K | -52.00K | 2.56M | 1.10M |
| Shares Outstanding (Basic) | 67.23M | 66.51M | 57.86M | 56.47M | 56.47M |
| Shares Outstanding (Diluted) | 69.99M | 66.51M | 57.86M | 56.47M | 56.47M |
| EPS (Basic) | 0.73 | -2.98 | -1.52 | -0.79 | -0.26 |
| EPS (Diluted) | 0.70 | -2.98 | -1.52 | -0.79 | -0.26 |
| EBITDA | 39.89M | -200.85M | -82.64M | -39.00M | 1.11M |
| Depreciation & Amortization | 1.09M | 487.00K | 52.00K | 1K | 13.55M |